Treatment
|
Study
|
OS
|
PFS
|
ORR
|
Overall SAEs
|
RP
|
Heterogeneity I2(%)
|
---|
| |
HR(95%CI)
|
HR(95% CI)
|
OR(95% CI)
|
OR(95% CI)
|
OR(95% CI)
|
OS
|
PFS
|
ORR
|
SAE
|
RP
|
---|
EP vs PC
|
[4,5,6]
|
0.85 (0.77–0.94)
|
0.66 (0.47–0.95)
|
1.0 (0.86–1.2)
|
1.2 (0.81–1.4)
|
0.48 (0.21–1.1)
|
0
|
0
|
59
|
0
|
27
|
PC-Cet vs PC
|
[7]
|
1.1 (0.84–1.4)
|
0.99 (0.8–1.2)
|
NR
|
1.2 (1.1–1.4)
|
0.56 (0.27–1.2)
| | | | | |
UP vs NP
|
[8]
|
0.86 (0.35–2.1)
|
0.68 (0.35–1.3)
|
1.6 (0.53–5.1)
|
0.47 (0.29–0.76)
|
0.88 (0.12–6.6)
| | | | | |
NP vs PP
|
[9]
|
1.7 (0.81–3.4)
|
1.6 (0.91–2.6)
|
1.4 (0.38–5.4)
|
1.9 (1.1–3.3)
|
5.7 (0.26–120.6)
| | | | | |
SP vs NP
|
[10]
|
0.85 (0.49–1.5)
|
0.37 (0.15–0.94)
|
0.79 (0.31–2.0)
|
0.67 (0.50–0.88)
|
1.3 (0.32–5.0)
| | | | | |
NP vs EP
|
[11]
|
0.93 (0.75–1.1)
|
NR
|
1.3 (0.82–1.9)
|
0.91 (0.81–1.0)
|
0.86 (0.50–1.5)
| | | | | |
PC vs DP
|
[12]
|
1.0 (0.33–3.3)
|
1.1 (0.48–2.3)
|
0.67 (0.23–2.0)
|
0.67 (0.39–1.2)
|
4.7 (0.22–101.6)
| | | | | |
PC vs GP
|
[12]
|
0.77 (0.34–1.8)
|
0.67 (0.3–1.5)
|
1.1 (0.40–3.0)
|
0.80 (0.45–1.4)
|
1.9 (0.17–22.5)
| | | | | |
DP vs GP
|
[12]
|
0.65 (0.28–1.5)
|
0.72 (0.36–1.5)
|
1.7 (0.56–4.9)
|
1.2 (0.70–2.0)
|
0.34 (0.01–8.8)
| | | | | |
MVP vs DP
|
[13]
|
1.2 (0.8–1.7)
|
1.2 (0.89–1.7)
|
0.64 (0.33–1.2)
|
1.8 (1.5–2.0)
|
0.67 (0.24–1.8)
| | | | | |
SP vs DP
|
[14]
|
0.81 (0.39–1.7)
|
1.1 (0.63–1.9)
|
1.2 (0.52–2.8)
|
0.49 (0.35–0.68)
|
0.10 (0.31–3.2)
| | | | | |
MVP vs IC
|
[15]
|
0.98 (0.74–1.3)
|
0.89 (0.69–1.1)
|
1.5 (0.95–2.5)
|
1.8 (1.5–2.0)
|
0.33 (0.06–1.6)
| | | | | |
MVP vs PC
|
[15]
|
0.95 (0.72–1.3)
|
1.1 (0.82–1.4)
|
1.2 (0.71–1.9)
|
2.1 (1.8–2.4)
|
0.33 (0.06–1.6)
| | | | | |
IC vs PC
|
[15]
|
1.1 (0.79–1.4)
|
1.1 (0.86–1.5)
|
0.75 (0.47–1.2)
|
1.2 (1.0–1.4)
|
1.0 (0.31–3.2)
| | | | | |
PP vs EP
|
[16]
|
0.98 (0.79–1.2)
|
0.86 (0.71–1.0)
|
1.1 (0.81–1.6)
|
0.96 (0.85, 1.1)
|
0.68 (0.21–2.2)
| | | | | |
PP vs PP-Cet
|
[17]
|
1.1 (0.58–2.0)
|
1.1 (0.62–1.8)
|
1.3 (0.54–3.3)
|
0.99 (0.74–1.3)
|
1.1 (0.32–3.6)
| | | | | |
- Abbreviations: OS overall survival, PFS progression-free survival, ORR objective response rate, SAEs serious adverse events, RP radiation pneumonitis, HR hazard ratio, CI confidence interval, OR odds ratio, EP etoposide-cisplatin, PC paclitaxel-cisplatin/carboplatin, UP uracil/tegafur(UFT)-cisplatin, NP vinorelbine-cisplatin, PP pemetrexed-cisplatin/carboplatin, SP S-1-cisplatin, DP docetaxel-cisplatin, GP gemcitabine-cisplatin, MVP mitomycin-vindesine-cisplatin, IC irinotecan-carboplatin, Cet cetuximab, NR not reported